- Home
- GCTS vs IMMX Comparison
GCTS vs IMMX Comparison
Compare GCTS & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCTS | IMMX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 82.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GCTS | IMMX |
|---|---|---|
| Price | $1.40 | $6.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $12.00 |
| AVG Volume (30 Days) | 119.6K | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,205.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $1.34 |
| 52 Week High | $2.76 | $7.73 |
Technical Indicators
Market Signals| Indicator | GCTS | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 66.71 |
| Support Level | $1.40 | $4.50 |
| Resistance Level | $1.49 | $7.73 |
| Average True Range (ATR) | 0.07 | 0.68 |
| MACD | 0.01 | 0.20 |
| Stochastic Oscillator | 52.38 | 65.44 |
Price Performance
Historical ComparisonAbout GCTS GCT Semiconductor Holding Inc.
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.